Previous 10 | Next 10 |
Processa Pharmaceuticals (NASDAQ: PCSA) , a diversified clinical-stage company developing products to improve survival and/or the quality of life for patients with unmet medical need conditions, today announced that its CEO Dr. David Young will present an update on Processa’s future therap...
HANOVER, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), Dr. David Young, Processa Pharmaceuticals, CEO will present an update on Processa’s future therapeutic focus and strategy at the upcoming Biotech Showcase on January 11, 2023, at 10 am. This prese...
A 0.5 mg daily dose of PCS12852 administered over 28 days in gastroparesis patients successfully improved gastroparesis symptoms in a clinically meaningful way as defined by greater than a 0.5 reduction in the ANMS GCSI-DD score compared to baseline. The percentage of patients who met the cli...
Processa Pharmaceuticals, Inc. (PCSA) Q3 2022 Earnings Conference Call November 08, 2022, 16:30 ET Company Participants Jim Stanker - CFO David Young - President & CEO Conference Call Participants Francois Brisebois - Oppenheimer Naz Rahman - Maxi...
The following slide deck was published by Processa Pharmaceuticals, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Processa Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation
Processa Pharmaceuticals press release ( NASDAQ: PCSA ): 9M GAAP EPS of -$0.90, compared to -$0.54 in 9M 2021. Our cash balance on September 30, 2022, was $9.1 million, which should be sufficient to complete our three on-going clinical trials and fund our operations into t...
PCS12852 successfully demonstrates a positive effect on the gastric emptying rate , clearing the path for a Phase 2B trial in 2023 . Next Generation Capecitabine (a combination of PCS6422 and capecitabine) successfu...
Processa Pharmaceuticals (NASDAQ: PCSA) , a diversified clinical-stage company developing products to improve survival and/or the quality of life for patients who have an unmet medical need condition, today announced positive results from its PCS12852 Phase 2A trial in patients with moderat...
In a Phase 2A Proof-of-Concept trial, the Gastric Emptying Breath Test (GEBT) results demonstrated statistical improvement in gastric emptying in gastroparesis patients receiving 0.5 mg of PCS12852 (6 patients) as compared to placebo (8 patients) at a p < 0.10 level. Adverse events...
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical need conditions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on ...
News, Short Squeeze, Breakout and More Instantly...
Processa Pharmaceuticals Inc. Company Name:
PCSA Stock Symbol:
OTCMKTS Market:
Processa Pharmaceuticals Inc. Website:
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, has named a new chief financial officer. According to the announcement, Russell L. Skibsted has accepted the new...
HANOVER, Md., July 17, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, announces the appointment of Ru...
Processa (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced positive efficacy results from the preliminary evaluation of its recently completed Phase 1b clinical trial. The...